Bharat Biotech's $75M Leap: India's Cell & Gene Therapy Revolution Begins.

Bharat Biotech International Ltd (BBIL) has launched India’s first vertically integrated Cell & Gene Therapy (C&GT) and Viral Vector Production facility at Genome Valley, Hyderabad, with a $75 million investment. This cutting-edge facility marks the company’s expansion beyond vaccines into regenerative and personalized medicine.

“With this milestone, we are pioneering advanced therapies that offer hope to millions,” said Dr. Krishna Ella, Executive Chairman of Bharat Biotech, at the inauguration. He emphasized the need for a strong regulatory framework to support research and innovation in this field.

Led by Chief Development Officer Raches Ella, the facility is equipped to manufacture high-titer viral vectors—including AAV, Lentivirus, and Adenovirus—critical for cell and gene therapy applications. These vectors play a key role in treating cancer, genetic disorders, and other life-threatening diseases. The facility also has the capability to develop platform products targeting blood cancers, solid tumors, and rare genetic conditions.

Currently, cell and gene therapies cost around ₹50 lakh per treatment, but indigenous production is expected to significantly reduce costs, improving accessibility. Bharat Biotech has five pipeline products—two in cell therapy and three in gene therapy—with the first expected to launch following clinical trials and regulatory approvals.

The company has partnered with the University of Wisconsin-Madison for research collaborations, which could expand into commercial agreements, including in-licensing opportunities. Bharat Biotech is also exploring exports and medical tourism potential for its advanced therapies.

Oncology and rare disease treatments are key focus areas, with the facility supporting next-generation therapies such as CD19 CAR T-cell therapy for blood cancers and gene therapy for inherited disorders. Dr. Krishanu Saha from the University of Wisconsin-Madison highlighted the role of AI-driven innovation in developing next-generation CAR cell therapies, which could transform patient care globally.

Spanning 50,000 sq ft, the GMP-certified facility is equipped with a state-of-the-art clean room setup, positioning Bharat Biotech at the forefront of advanced medical treatments. By addressing critical unmet clinical needs, the company aims to drive innovation in the global cell and gene therapy landscape.

News by Rahul Yelligetti.